Soleno Therapeutics (SLNO) Assets (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Assets of $608.4 million for Q1 2026, up 91.26% year-over-year from $318.1 million in Q1 2025, and up 7.9% quarter-over-quarter from $563.8 million in Q4 2025.
Soleno Therapeutics (SLNO) Assets (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Assets for 14 consecutive years, with $608.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 91.26% year-over-year to $608.4 million; the TTM figure through Mar 2026 stood at $608.4 million (up 91.26% YoY), while the FY2025 annual figure was $563.8 million, up 70.36% from the prior year.
- Assets grew to $608.4 million in Q1 2026 per SLNO's latest filing, from $563.8 million in the prior quarter.
- Across five years, Assets topped out at $608.4 million in Q1 2026 and bottomed at $19.5 million in Q1 2023.
- Historically, Assets has averaged $232.7 million across 5 years, with a median of $180.7 million in 2023.
- Annual changes were most pronounced in 2023 — Assets slumped 54.08% — and 2024, when it soared 882.84%.
- Soleno Therapeutics' Assets stood at $26.5 million in 2022, then jumped by 581.93% to $180.7 million in 2023, then soared by 83.17% to $331.0 million in 2024, then jumped by 70.36% to $563.8 million in 2025, then advanced by 7.9% to $608.4 million in 2026.
- Business Quant data shows SLNO's Assets at $608.4 million in Q1 2026, $563.8 million in Q4 2025, and $599.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 608.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 608.39 Mn |
| Dec 31, 2025 | 563.83 Mn |
| Sep 30, 2025 | 599.90 Mn |
| Jun 30, 2025 | 332.31 Mn |
| Mar 31, 2025 | 318.09 Mn |
| Dec 31, 2024 | 330.97 Mn |
| Sep 30, 2024 | 296.71 Mn |
| Jun 30, 2024 | 304.13 Mn |
| Mar 31, 2024 | 168.84 Mn |
| Dec 31, 2023 | 180.69 Mn |
| Sep 30, 2023 | 63.55 Mn |
| Jun 30, 2023 | 30.94 Mn |
| Mar 31, 2023 | 19.54 Mn |
| Dec 31, 2022 | 26.50 Mn |
| Sep 30, 2022 | 31.98 Mn |
| Jun 30, 2022 | 36.86 Mn |
| Mar 31, 2022 | 42.55 Mn |
| Dec 31, 2021 | 35.55 Mn |
| Sep 30, 2021 | 42.57 Mn |
| Jun 30, 2021 | 48.78 Mn |